New Humira alternatives will be available in July. This could make the drug that now costs nearly $80,000 per year more affordable.
as a direct challenge to unaffordable drugs and complex pricing strategies in the pharmaceutical industry. By negotiating directly with drug makers and insurance companies, instead of working through PBMs, Cost Plus Drugs offers medications at significant discounts. It will do the same with Humira.Partnering with Coherus Biosciences, Cost Plus Drugs will offer Humira alternative Yusimry at its manufacturing cost plus 15%, totaling about $569 before shipping and dispensing fees.
Yusimry’s lower price also will be attractive to employers, Oshmyansky said. Employers typically cover“We’ve had an enormous amount of interest from the employer community,” he said. “Because at the end of the day, who’s paying for most of the medications? It’s employers. We should be able to save employers and payers more broadly substantial amounts of money going through our channels, as opposed to conventional ones.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
New taxes, higher tolls, and more: These new laws take effect in Washington on July 1From taxes to tolls, here's what you need to look out for starting July 1.
Weiterlesen »
Fourth of July 2023: Where to attend July 4 parades in N.J.Check out this list of Fourth of July parades planned throughout New Jersey in 2023.
Weiterlesen »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Weiterlesen »
For AbbVie’s blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayLower-price biosimilar competition for top-selling drug launching this weekend.
Weiterlesen »